Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the
progression of Parkinson symptoms in patients with early PD. The primary outcome will be the
time to progression of disability warranting initiation of L-dopa or a dopamine agonist.
Secondary outcomes will comprise assessments of symptoms, activities of daily living and
global clinical status.